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One of the key ways to translate new basic discoveries into clinical
relevance is the analysis of gene expression in tumour samples,
relating this to various outcomes. These may include relapse-free
survival and overall survival, sites of metastasis and, of course,
differential expression in tumour vs normal is important to
describe. The above are prognostic factors, but use of markers to
predict which patients will benefit from increasingly complex and
expensive therapies is potentially of high utility and a logical follow
on, once patients with poor prognosis are selected. To achieve the
goal of individualised medicine, with the selection of correct
therapy for the molecular pathways in the tumour, this approach is
needed.
When a new marker or protein is discovered and investigated in
this way, there are often many failings in the initial phase of the
development and validation. Examples include initial small studies
that are made because the investigators do not have good access to
clinical material. There may be many small studies, none of which
have the individual statistical power to really test the significance
of the marker. Owing to the small studies they may have
wide variability in the statistical reliability and even opposite
results. Very few of them seem to describe the number of cases that
are needed to adequately test significantly the factor being
examined.
The assays themselves, being research based, may be poorly
validated and not well described, certainly not including the
reproducibility interassay variation and other measures of
reproducibility and standardisation. This is particularly the case
in immunohistochemical studies but often with other quantitative
assays such as Western blotting and ELISAs. These sources of
variability may explain early controversies in the literature when
new markers are described by different groups.
The paper by McShane et al (2005) published on pages 387–391
in this issue of BJC, represents several years of discussion from
experts in this area, representing European and USA groups, who
have produced a consensus on how to design and present these
studies. These recommendations will be published simultaneously
by several journals and produce a recommended standard that will
help solve some of these problems.
Although their recommendations apply to prognostic factors,
they are also applicable to predictive factors. Many important
randomised trials now have 5–10 years follow-up, from which the
basis for the current and future therapy is derived, for example, the
adjuvant therapy of breast cancer. Defining the groups of patients
who benefit from chemotherapy or endocrine therapy has
substantial implications for patient selection, design of future
trials and cost effectiveness. These trials have 1000s of patients
in them and are an ideal way to test both predictive and prognostic
factors. The only way predictive factors can really be tested is
in randomised trials where one treatment is compared to
another or no treatment and the value of a test to predict
response to therapy would also need to be validated in further
studies.
The development of well-characterised tissue microarrays has
expedited the ability to analyse markers and pathways and many
new techniques being applied to these, including extraction of
DNA for comparative genome hybridisation and new methods to
extract RNA, thus being able to carry out reverse transcription and
quantitative polymerase chain reaction (rtPCR) assays to derive
gene profiles (Paik et al, 2004). The latter study demonstrates how
a rigorous approach in development of assay methodology can be
applied to retrospective material effectively. Even larger numbers
of samples can be studied with new techniques, providing not only
greater statistical strength but also further technical challenges
(Rimm, 2005).
It is particularly important that these types of studies are
comparable and can be validated between studies to maximise
information that will be available from them. However, these
observations apply not just to these large retrospective analyses
but also to new prospective studies and the validation of new
markers on frozen material. Many basic techniques that are
presented, including rtPCR, Western blotting, immunochemistry,
really do not have a rigorous standardisation that will allow
reproducibility.
To some extent this is a problem also generated by Journals that
want to minimise the amount of space used in Methods Sections
and therefore will prevent authors describing results in a way that
would allow rigorous replication. However, one would hope that
with the increasing access to web material, these detailed protocols
would be available and indeed that this would be a requirement in
the future for new markers, to be able to link the detailed
validation to the short Methods Section in the papers.
Considering the increasing ethical issues and difficulties with
accessing human material from trials prospectively and retro-
spectively (although these are being overcome), it is particularly
important that when they are subjected to assay that the latter are
of better quality, validated and reproducible.
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www.bjcancer.comIt is interesting to note that where assays have major therapeutic
implications then rapid, often commercial reliable testing does
become available, for example use of Herceptin and FISH analysis
of tumour samples. However, in spite of the use of endocrine
therapy for over 30 years, the immunohistochemical analyses for
oestrogen and progesterone receptors still do not seem to have an
adequate international standardisation.
The BJC considers the publication of prognostic studies
and predictive studies as an important component of trans-
lational research and we would expect authors submit-
ting papers to this area to be aware of and to follow
these guidelines. Further detailed evaluation of methodology
and validation of assays can be accepted as supplementary
material.
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